CN105412058A - Novel application of acetylcysteine - Google Patents

Novel application of acetylcysteine Download PDF

Info

Publication number
CN105412058A
CN105412058A CN201510884575.9A CN201510884575A CN105412058A CN 105412058 A CN105412058 A CN 105412058A CN 201510884575 A CN201510884575 A CN 201510884575A CN 105412058 A CN105412058 A CN 105412058A
Authority
CN
China
Prior art keywords
acetylcysteine
essence
poloxamer
purposes
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201510884575.9A
Other languages
Chinese (zh)
Inventor
毛慧华
邱东旭
郝桂彤
王月然
姜来
刘昊川
周密
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TIANJIN KUNJIAN BIOLOGICAL PHARMACEUTICAL CO Ltd
Original Assignee
TIANJIN KUNJIAN BIOLOGICAL PHARMACEUTICAL CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TIANJIN KUNJIAN BIOLOGICAL PHARMACEUTICAL CO Ltd filed Critical TIANJIN KUNJIAN BIOLOGICAL PHARMACEUTICAL CO Ltd
Priority to CN201510884575.9A priority Critical patent/CN105412058A/en
Publication of CN105412058A publication Critical patent/CN105412058A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Abstract

The invention provides novel application of the acetylcysteine; the acetylcysteine is suitable for treating oral ulcer; and an acetylcysteine gel, which is prepared according to the application, simultaneously has medicinal functions of rapidly relieving pain and preventing ulcer, and specifically inhibiting further spread of ulcer in patients receiving radiotherapy, chemotherapy and bone marrow transplantation and promoting wound healing.

Description

The novelty teabag of acetylcysteine
Technical field
The present invention relates to new medicine use, especially the novelty teabag of acetylcysteine.
Background technology
China has an appointment 3,200,000 cancer patients every year, forms grave danger to China's national health.Radiotherapy chemotherapy and carry out bone marrow transplantation therapy and become the anticancer conventional means of patient, can receive significant therapeutic effect.But these means to suppress while cancerous tumor cell also to cause infringement in various degree, with each para-infectious generation to human autoimmune's system.And as non-cornified position, oral mucosa generation ulcer accepts the complication that radiotherapy patient the most easily occurs, and especially accept the patient of head radiotherapy, its oral ulcer sickness rate is close to 100%.The symptom main manifestations of oral ulcer is: erythroplakia, edema, ulcer, simultaneously hurt like hell, hinders patients diet etc.The generation of oral ulcer not only have impact on the quality of life of cancer patient, the expection process that what is more important can disturb it to treat, even some patients due to serious oral ulcer therapy discontinued.At present, clinicist lacks effective medicine and means for the nursing of this type of patient's oral ulcer with treatment.Clinically, the process means common for the problems referred to above are more conservative, are confined to strengthen mouth care, and saline solution rinses, and regularly brushes teeth, avoids pungent, heat, acid or roughage, avoid drinking carrying out the aspects such as physical method alleviation with smoking and with ice cube.Therefore, for the demand of this type of patient, develop dental ulcer treatment new drug targetedly, for the survival condition improving cancer patient, the means enriching domestic assistant treating cancer have important practical significance.
Acetylcysteine (N-acetylcysteine) is the precursor substance of Intracellular Glutathione (GSH), it directly can remove interior free yl, enhancing body anti-oxidation stress ability, and the generation of inflammatory cytokine, chemotactic factor and adhesion molecule can be reduced.In addition, acetylcysteine can also regulate immune status and apoptotic program.Because acetylcysteine has the pharmacological action of significant antioxidant activity and conditioner body immunity function, simultaneously, multiple intricate and close contacting is there is between response to oxidative stress and inflammatory reaction, present stage, acetylcysteine is as the oral expectorant of one, be applicable to the patient that the coughs such as a chronic bronchitis have sticky expectorant and not easily expectoration, especially applicable child uses.And have huge realistic meaning for the deep excavation of acetylcysteine medical value with exploitation.
Summary of the invention
Technical problem to be solved by this invention is the novelty teabag providing acetylcysteine.
For solving the problems of the technologies described above, technical scheme of the present invention is:
The purposes of acetylcysteine in the medicine for the preparation for the treatment of oral ulcer.
Preferably, the purposes of above-mentioned acetylcysteine, the described medicine being used for the treatment of oral ulcer is acetylcysteine gel agent, and active component is made up of acetylcysteine and poloxamer, and the weight ratio of described acetylcysteine and poloxamer is 1-30: 5-30.
Preferably, the purposes of above-mentioned acetylcysteine, the working concentration of described poloxamer is 10%-25% (w/v).
Preferably, the purposes of above-mentioned acetylcysteine, also comprises stabilizing agent, correctives and antiseptic, by its weight parts acetylcysteine 1-30 part, poloxamer 5-30 part, stabilizing agent 0.05-1.5 part, correctives 0.01-5.0 part, antiseptic 0.05-1.0 part, wherein
Described stabilizing agent is one or more in sodium sulfite, sodium pyrosulfite, sodium sulfite, sodium thiosulfate, ascorbic acid, thiourea, methionine, ethylenediaminetetraacetic acid, disodiumedetate, sodium citrate;
Described correctives comprises sweeting agent and/or essence, and described sweeting agent is one or more in sucrose, saccharin sodium, steviosin, glucose, maltose, aspartame, sucralose, xylitol, erythritol; Described essence is one or more in strawberry essence, osmanthus flower fragrance, flavoring orange essence, Fructus Pyracanthae essence, Fructus Mangifera Indicae essence, Mint Essence, Fructus Citri Limoniae essence;
Described antiseptic is one or more in methyl parahydroxybenzoate, ethylparaben, propyl p-hydroxybenzoate, benzoic acid, sodium benzoate, sorbic acid, potassium sorbate, calcium sorbate, benzalkonium bromide.
Preferably, the purposes of above-mentioned acetylcysteine, wherein,
Described stabilizing agent is one or more in sodium pyrosulfite, sodium sulfite, sodium thiosulfate, ethylenediaminetetraacetic acid, disodiumedetate, sodium citrate;
Described correctives comprises sweeting agent and/or essence, and described sweeting agent is one or more in sucrose, glucose, aspartame, sucralose, xylitol; Described essence is one or more in strawberry essence, flavoring orange essence, Fructus Citri Limoniae essence;
Described antiseptic is one or more in methyl parahydroxybenzoate, ethylparaben, sodium benzoate, potassium sorbate.
Preferably, the purposes of above-mentioned acetylcysteine, described acetylcysteine gel agent is prepared by following method:
(1) purified water is cooled, logical N in cooling procedure 2, in cooled purified water, add the acetylcysteine of prescription amount, stabilizing agent and correctives and be uniformly mixed;
(2) in whipping process, by alkaline solution adjust ph to 5.0-7.0, after mucolyticum acid dissolve, add antiseptic and the poloxamer of prescription amount, be stirred to poloxamer and dissolve, leave standstill 12-24h, obtain acetylcysteine gel agent.
Preferably, the purposes of above-mentioned acetylcysteine, described in described step (1), purified water is cooled to 0-20 DEG C, logical N 2to dissolved oxygen amount < 2ppm.
Preferably, the purposes of above-mentioned acetylcysteine, described in described step (2), alkaline solution will be cooled to 0-20 DEG C in preparation process, simultaneously logical N2, logical N 2rear dissolved oxygen < 2ppm.
Control the dissolubility that low temperature can significantly improve poloxamer in said method, shorten the preparation time of gel; Control low dissolved oxygen and PH can significantly improve the stability of ethionamide.
Preferably, the purposes of above-mentioned acetylcysteine, in described step (2), the working concentration of poloxamer is 10%-25% (w/v), can ensure that gel has higher viscosity and keep liquid condition always in preparation process in this amount ranges.
Preferably, the purposes of above-mentioned acetylcysteine, in described step (2), poloxamer will improve mixing speed in adition process, and in course of dissolution, gel viscosity can constantly increase, and will adjust mixing speed at any time and keep whirlpool state until poloxamer dissolves completely; High mixing speed can promote that poloxamer dissolves, and reduces in preparation process the bubble produced, and the more important thing is and ensure that finally preparing product dosage form is gel.
Preferably, the purposes of above-mentioned acetylcysteine, described acetylcysteine gel agent is prepared by following method:
(1) purified water is cooled to 0-20 DEG C, logical N in cooling procedure 2to dissolved oxygen amount < 2ppm, in cooled purified water, add the acetylcysteine of prescription amount, stabilizing agent and correctives and be uniformly mixed;
(2) in whipping process, with temperature 0-20 DEG C, logical N 2the alkaline solution adjust ph of rear dissolved oxygen < 2ppm is to 5.0-7.0, after mucolyticum acid dissolve, add antiseptic and the poloxamer of prescription amount, improve mixing speed formation whirlpool and dissolve to poloxamer, leave standstill 12-24h, obtain acetylcysteine gel agent.
The dissolved oxygen amount < 2ppm of the N2 mentioned in technique scheme, refers to dissolved oxygen amount generally at 0.5-2ppm.
The invention has the beneficial effects as follows:
The invention provides a kind of novelty teabag of acetylcysteine, can be used for treating oral ulcer, the medicine realizing this purposes can be acetylcysteine gel agent, active component acetylcysteine and poloxamer (mucosa film former) in high dissolution, dispersity, film former poloxamer is after oral mucosa surface coverage, first blocked the contact of ulcer and internal environment of oral cavity, the pain caused by internal environment of oral cavity factor can have been alleviated rapidly; Secondly, poloxamer has played the effect of pharmaceutical carrier, while formation mucosa covers, acetylcysteine is delivered to ulcer local, play its pharmacological action, reach the object promoting ulcer healing, can rapid pain relief be played to the oral ulcer that many reasons causes, block ulcer aggravation, accelerate the effect of ulcer surface healing.
Described acetylcysteine gel agent has been had both rapid pain relieving simultaneously, has been prevented and treated ulcer, particularly can suppress to accept the continuous enlargement of Radiotherapy chemotherapy and bone marrow transplantation therapy patient ulcer and the medicinal efficacy of wound healing; Preparation technology is simple, be easy to realize industrial-scale production, and product uniformity is good, stability is high, modest viscosity, active component are single clearly, quality controllability is good, enriched the kind of clinical cancer auxiliary treatment medication, the nursery work for radiotherapy group provides good selection.
Accompanying drawing explanation
Fig. 1 is blank group and accepts oral mucosa photo before radiation.
Fig. 2 is blank group and accepts oral mucosa photo after radiation.
Fig. 3 is that high dose administration group accepts oral mucosa photo after radiation.
Fig. 4 is that middle dosed administration group accepts oral mucosa photo after radiation.
Fig. 5 is that low dosage administration group accepts oral mucosa photo after radiation.
Detailed description of the invention
In order to make those skilled in the art better understand technical scheme of the present invention, below in conjunction with the drawings and the specific embodiments, technical scheme of the present invention is described in further detail.
Embodiment 1
75g purified water is cooled to 10 DEG C, logical N in cooling procedure 2to dissolved oxygen amount < 2ppm (about 1.7ppm), add 10g acetylcysteine, 0.05g ethylenediaminetetraacetic acid, 0.5g sodium citrate and 0.05g sucralose and be uniformly mixed in whipping process, with temperature 10 DEG C, logical N 2the alkaline solution adjust ph to 6.0 of rear dissolved oxygen < 2ppm (about 1.7ppm), after mucolyticum acid dissolve, add 0.1g methyl parahydroxybenzoate and 15g poloxamer (working concentration is 20% (w/v)), improve mixing speed formation whirlpool to dissolve to poloxamer, leave standstill 24h, filter, i.e. obtained acetylcysteine gel agent.
Embodiment 2
70g purified water is cooled to 1 DEG C, logical N in cooling procedure 2to dissolved oxygen amount < 2ppm (about 1.9ppm), add 30g acetylcysteine, 0.1g sodium pyrosulfite and 0.1g sucrose and be uniformly mixed, in whipping process, with temperature 1 DEG C, logical N 2the alkaline solution adjust ph to 7.0 of rear dissolved oxygen < 2ppm (about 1.9ppm), after mucolyticum acid dissolve, add 0.2g sodium benzoate and 20g poloxamer (working concentration is 10% (w/v)), improve mixing speed formation whirlpool to dissolve to poloxamer, leave standstill 12h, filter, i.e. obtained acetylcysteine gel agent.
Embodiment 3
75g purified water is cooled to 20 DEG C, logical N in cooling procedure 2to dissolved oxygen amount < 2ppm (about 1.8ppm), add 20g acetylcysteine, 0.7g sodium thiosulfate and 3.0g aspartame and be uniformly mixed, in whipping process, with temperature 20 DEG C, logical N 2the alkaline solution adjust ph to 5.0 of rear dissolved oxygen < 2ppm (about 1.8ppm), after mucolyticum acid dissolve, add 1.0g potassium sorbate and 13g poloxamer (working concentration is 25% (w/v)), improve mixing speed formation whirlpool to dissolve to poloxamer, leave standstill 18h, add 0.05g Fructus Citri Limoniae essence dissolution filter, i.e. obtained acetylcysteine gel agent.
Embodiment 4
75g purified water is cooled to 5 DEG C, logical N in cooling procedure 2to dissolved oxygen amount < 2ppm (about 1.7ppm), add 20g acetylcysteine, 1.5g sodium sulfite and 1.5g glucose and be uniformly mixed, in whipping process, with temperature 10 DEG C, logical N 2the alkaline solution adjust ph to 6.0 of rear dissolved oxygen < 2ppm (about 1.8ppm), after mucolyticum acid dissolve, add 0.07g ethylparaben and 17g poloxamer (working concentration is 15% (w/v)), improve mixing speed formation whirlpool to dissolve to poloxamer, leave standstill 20h, add 0.1g flavoring orange essence dissolution filter, i.e. obtained acetylcysteine gel agent.
Embodiment 5
75g purified water is cooled to 15 DEG C, logical N in cooling procedure 2to dissolved oxygen amount < 2ppm (about 1.8ppm), add 20g acetylcysteine, 1.0g disodiumedetate and 4.0g xylitol and be uniformly mixed, in whipping process, with temperature 10 DEG C, logical N 2the alkaline solution adjust ph to 7.0 of rear dissolved oxygen < 2ppm (about 1.9ppm), after mucolyticum acid dissolve, add 0.03g ethylparaben, 0.05g methyl parahydroxybenzoate and 20g poloxamer (working concentration is 20% (w/v)), improve mixing speed formation whirlpool to dissolve to poloxamer, leave standstill 15h, add 1.0g strawberry essence dissolution filter, i.e. obtained acetylcysteine gel agent.
Using method is: get gained acetylcysteine gel agent 10ml in above-described embodiment, oral cavity rinsing the mouth spued after 1 minute, and every day uses 3-5 time.
The safety evaluatio of main component
1. acetylcysteine safety evaluatio
Zoopery dissimilar in a large number is for many years verified, and under multiple administering mode, acetylcysteine all demonstrates great tolerance dose.Meanwhile, the acetylcysteine applicating history of existing more than 30 year clinically, the most data from health volunteer and acetaminophen excessive use patient confirms its safety of applying.A result of study display that continue for 2 years, the dose of virtual safe scope of oral acetylcysteine is 8.6mg/kg/day ~ 60mg/kg/day.
2. f127 safety evaluatio
In general, in any prescription f127 does not participate in internal metabolism.For rat, when injection gives the dosage of 1.5g/kg, the elimination half-life of F127 is about 21h, and in 24h, the overwhelming majority is by urine drains, and about 5% by hepatic excretion, and 1% is fallen by renal excretion.From a research report display of Germany of production firm BASF, f127 non-display system in laboratory animal Canis familiaris L. body absorbs.Canis familiaris L. intra-arterial is given after F127 (100mg/kg), in 30h 75% f127 discharges from urine with archetypal molecule, similar to the situation in rat body, shows good safety.After above-mentioned zooperal result is analyzed, can predict it is negligible that F127 carries out absorbing by the oral mucosa that the mankind are impaired the amount entering body circulation.Safe using poloxamer as oral mucosa film former in the present invention.
The drug effect checking of acetylcysteine gel agent of the present invention:
The drug effect of mode to acetylcysteine gel agent of the present invention that drug effect demonstration test have employed the modeling of 60Co gamma-rays irradiation laboratory animal oral mucosa is verified.
Laboratory animal: healthy Golden Hamster 40, male and female half and half, about body weight 100g.
Animal divides into groups: laboratory animal is divided into 4 groups at random, often organize 10,4 groups of laboratory animals are respectively blank group and low dose group (medicament contg is 5%), middle dosage group (medicament contg is 10%) and high dose group (medicament contg is 15%), and low dose group, middle dosage group and high dose group all adopt the agent of embodiment 1 gained acetylcysteine gel.
Modeling and administration: the radiological dose of employing is 80Gy, irradiation distance 80cm, 2 times/week, Continuous irradiation 3 times, irradiates administration of dividing into groups next day, 3 times/day for the last time; Naive animals gives purified water.
Administering mode: place smears in animal oral cavity ulcer.
Result of the test is shown in Fig. 1-Fig. 5: test proceeds to the 9th day, and naive animals oral mucosa all shows as 5 grades of deep ulcers; Low dose group 9 animal oral cavity mucosas are in 5 grades of deep ulcer states, and 1 is in 4 grades of ulcer; Middle dosage group has 7 to be in 4 grades of ulcer states, and 1 is in 5 grades of ulcer states, and 2 are in 3 grades of ulcer states; In high dose group, 8 laboratory animal oral mucosas are in 3 grades of ulcer states, and 1 is in 2 grades of ulcer states, and 1 is in 4 grades of ulcer states.This result of the test shows, the oral ulcer that acetylcysteine gel agent of the present invention causes for being subject to radiation has practical protection and therapeutical effect.
Experiment proves, the oral ulcer that acetylcysteine gel agent of the present invention causes for being subject to radiation has practical protection and therapeutical effect.
Experiment proves, acetylcysteine gel agent of the present invention has practical protection and therapeutical effect for ulcer after carrying out chemotherapy or bone marrow transplantation therapy.
Above-mentioned detailed description of the novelty teabag of this acetylcysteine being carried out with reference to detailed description of the invention; illustrative instead of determinate; several embodiments can be listed according to institute's limited range; therefore in the change do not departed under general plotting of the present invention and amendment, should belong within protection scope of the present invention.

Claims (10)

1. the purposes of acetylcysteine in the medicine for the preparation for the treatment of oral ulcer.
2. the purposes of acetylcysteine according to claim 1, it is characterized in that: described in be used for the treatment of oral ulcer medicine be acetylcysteine gel agent, active component is made up of acetylcysteine and poloxamer, and the weight ratio of described acetylcysteine and poloxamer is 1-30: 5-30.
3. the purposes of acetylcysteine according to claim 2, is characterized in that: the working concentration of described poloxamer is 10%-25% (w/v).
4. the purposes of acetylcysteine according to claim 2, it is characterized in that: also comprise stabilizing agent, correctives and antiseptic, by its weight parts acetylcysteine 1-30 part, poloxamer 5-30 part, stabilizing agent 0.05-1.5 part, correctives 0.01-5.0 part, antiseptic 0.05-1.0 part, wherein
Described stabilizing agent is one or more in sodium sulfite, sodium pyrosulfite, sodium sulfite, sodium thiosulfate, ascorbic acid, thiourea, methionine, ethylenediaminetetraacetic acid, disodiumedetate, sodium citrate;
Described correctives comprises sweeting agent and/or essence, and described sweeting agent is one or more in sucrose, saccharin sodium, steviosin, glucose, maltose, aspartame, sucralose, xylitol, erythritol; Described essence is one or more in strawberry essence, osmanthus flower fragrance, flavoring orange essence, Fructus Pyracanthae essence, Fructus Mangifera Indicae essence, Mint Essence, Fructus Citri Limoniae essence;
Described antiseptic is one or more in methyl parahydroxybenzoate, ethylparaben, propyl p-hydroxybenzoate, benzoic acid, sodium benzoate, sorbic acid, potassium sorbate, calcium sorbate, benzalkonium bromide.
5. the purposes of acetylcysteine according to claim 4, is characterized in that: wherein,
Described stabilizing agent is one or more in sodium pyrosulfite, sodium sulfite, sodium thiosulfate, ethylenediaminetetraacetic acid, disodiumedetate, sodium citrate;
Described correctives comprises sweeting agent and/or essence, and described sweeting agent is one or more in sucrose, glucose, aspartame, sucralose, xylitol; Described essence is one or more in strawberry essence, flavoring orange essence, Fructus Citri Limoniae essence;
Described antiseptic is one or more in methyl parahydroxybenzoate, ethylparaben, sodium benzoate, potassium sorbate.
6. the purposes of acetylcysteine according to claim 2, is characterized in that: described acetylcysteine gel agent is prepared by following method:
(1) purified water is cooled, logical N in cooling procedure 2, in cooled purified water, add the acetylcysteine of prescription amount, stabilizing agent and correctives and be uniformly mixed;
(2) in whipping process, by alkaline solution adjust ph to 5.0-7.0, after mucolyticum acid dissolve, add antiseptic and the poloxamer of prescription amount, be stirred to poloxamer and dissolve, leave standstill 12-24h, obtain acetylcysteine gel agent.
7. the purposes of acetylcysteine according to claim 6, is characterized in that: described in described step (1), purified water is cooled to 0-20 DEG C, logical N 2to dissolved oxygen amount < 2ppm.
8. the purposes of acetylcysteine according to claim 6, is characterized in that: described in described step (2), alkaline solution will be cooled to 0-20 DEG C in preparation process, simultaneously logical N 2, logical N 2rear dissolved oxygen < 2ppm.
9. the purposes of acetylcysteine according to claim 6, it is characterized in that: in described step (2), the working concentration of poloxamer is 10%-25% (w/v), can ensure that gel has higher viscosity and keep liquid condition always in preparation process in this amount ranges.
10. the purposes of acetylcysteine according to claim 6, is characterized in that: described acetylcysteine gel agent is prepared by following method:
(1) purified water is cooled to 0-20 DEG C, logical N in cooling procedure 2to dissolved oxygen amount < 2ppm, in cooled purified water, add the acetylcysteine of prescription amount, stabilizing agent and correctives and be uniformly mixed;
(2) in whipping process, with temperature 0-20 DEG C, logical N 2the alkaline solution adjust ph of rear dissolved oxygen < 2ppm is to 5.0-7.0, after mucolyticum acid dissolve, add antiseptic and the poloxamer of prescription amount, improve mixing speed formation whirlpool and dissolve to poloxamer, leave standstill 12-24h, obtain acetylcysteine gel agent.
CN201510884575.9A 2015-12-04 2015-12-04 Novel application of acetylcysteine Pending CN105412058A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510884575.9A CN105412058A (en) 2015-12-04 2015-12-04 Novel application of acetylcysteine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510884575.9A CN105412058A (en) 2015-12-04 2015-12-04 Novel application of acetylcysteine

Publications (1)

Publication Number Publication Date
CN105412058A true CN105412058A (en) 2016-03-23

Family

ID=55490915

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201510884575.9A Pending CN105412058A (en) 2015-12-04 2015-12-04 Novel application of acetylcysteine

Country Status (1)

Country Link
CN (1) CN105412058A (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103027891A (en) * 2012-11-25 2013-04-10 天津坤健生物制药有限公司 Acetylcysteine gargle for treating dental ulcers, and preparation method thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103027891A (en) * 2012-11-25 2013-04-10 天津坤健生物制药有限公司 Acetylcysteine gargle for treating dental ulcers, and preparation method thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
R.C.罗: "《药用辅料手册》", 31 January 2005, 化学工业出版社，现代生物技术与医药科技出版中心出版发行 *
郭圣荣主编: "《医药用生物降解性高分子材料》", 31 January 2004, 化学工业出版社&现代生物技术与医药科技出版中心 *

Similar Documents

Publication Publication Date Title
US11896567B2 (en) Combination composition
CN103027891A (en) Acetylcysteine gargle for treating dental ulcers, and preparation method thereof
CN105307647A (en) Oral antiseptic composition for treating oral mucositis
AU2024200203A1 (en) Methods for the treatment of recurrent glioblastoma (RGBM)
PL188153B1 (en) Drug and manner of exterting a pharmacological effect on human organism by such drug
JPH04243825A (en) Remedy for pigmentation
CN105311081A (en) Application of Shanhaidan chrysanthemum indicum injection in aerosol inhalation, spray bottle aerial fog and rectal administration and method
ES2652266T3 (en) Solid oral dosage composition of ibuprofen comprising a methacrylic acid copolymer
CN105380957A (en) Acetylcysteine gel, and preparation method and application thereof
Huntington et al. Intra‐arterial Bleomycin therapy in inoperable squamous cell carcinomas
CN105412058A (en) Novel application of acetylcysteine
WO2012005605A1 (en) A combination composition comprising ibuprofen and paracetamol
JP4903694B2 (en) Use of calcium trifluoroacetate for the manufacture of a medicament with anti-angiogenic activity
CN104758348B (en) A kind of Chinese medicine composition preparation is used for the purposes of tumor chemoradiotherapy related oral ulcer
RU2099065C1 (en) Preparation and method for treating local complications occurring during conservative antitumoral treatment in oropharyngeal zone
CN111000871A (en) Oral cavity spray and preparation method thereof
WO2012156502A2 (en) Two component mouth rinse preparation
CN102716465B (en) Pharmaceutical composite for treating tumor and preparation method of pharmaceutical composite
US20110256237A1 (en) Methods and compositions for treating acne vulgaris and acne rosacea
WO2011133010A2 (en) Molecular iodine composition for human use for the prevention and treatment of prostatic pathologies
CN104173372A (en) Composition for treating oral mucositis, as well as preparation method and application package thereof
CN107260682A (en) A kind of ion VC powder sprays and preparation method thereof
CN102698252B (en) Medicine composition for treating tumor and preparation method for medicine composition
SU449724A1 (en) Mukaltin Expectorant
ES2822659T3 (en) Effervescent tablet

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20160323

RJ01 Rejection of invention patent application after publication